Max Healthcare Institute LtdQ1 FY25
Max Healthcare Institute Ltd Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,081P/E: 70.0Market Cap: ₹1.0L CrSector: Healthcare Services
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- →Max Healthcare expects strong growth driven by recent acquisitions (Lucknow, Nagpur, Jaypee Noida) and new facilities (Dwarka, brownfield expansions).
- →FY '25 revenue saw a 26% YoY growth and 22% growth in EBITDA.
- →New brownfield expansions adding around 1,500 beds in FY '26 are expected to ramp up quickly, improving occupancy and margins.
- →Greenfield projects like Gurgaon will take longer to mature but contribute incremental revenue over time.
- →Average Revenue Per Occupied Bed (ARPOB) is growing (~7% YoY growth in existing hospitals).
- →Increased institutional and international business will contribute, though international patients may not move the needle significantly at new locations initially.
- →Network operating EBITDA margin was 27.2% for Q4 FY '25, with potential margin expansion from brownfield expansions.
- →Overall, the company is targeting capacity tripling over the next 5 years backed by ongoing expansions and acquisitions.
Margin guidance
Category 3- →Strong earnings and EBITDA growth expected driven by capacity expansion and acquisitions.
- →Brownfield expansions (~1,400-1,500 beds in FY26) to deliver higher EBITDA margins due to lower incremental fixed costs.
- →Newly acquired units (Lucknow, Nagpur, Noida) showing robust revenue and EBITDA growth, with further margin expansion potential as capacity and specialties ramp up.
- →Greenfield facilities like Dwarka achieved record EBITDA breakeven within 6 months; similar trajectory expected for Gurgaon facility.
- →Network-wide EBITDA margin was 27.2% this quarter; Existing units margin at 28.5%, with scope for improvement from expansions.
- →Management confident of continued strong cash flows and ROCE (FY25 ROCE at 26%), supporting capacity doubling over next 4-5 years.
- →Guidance indicates a growing bed capacity target (9,000 beds by 2028, likely to increase with acquisitions), supporting long-term earnings growth.
- →Positive ARPOB growth (7% YoY for existing units) and sustained occupancy at ~75% underpin revenue and profit growth.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →The company has very little leverage on its balance sheet currently and is happy to go up to 2.5x net debt to EBITDA.
- →Expansion will mostly be funded through internal accruals, with more than enough room to acquire with existing cash and balance sheet capacity.
- →Recent increase in interest cost is primarily due to INR 1,000 crore borrowed for the Jaypee acquisition and INR 600 crore loan for the Sahara acquisition.
- →Unless there are major acquisitions, no significant change in interest cost or additional borrowing is expected.
- →The company remains open to acquisitions if they meet ROCE and strategic criteria but does not provide guidance until deals are closed.
- →No specific mention of immediate planned new fundraising via debt or equity beyond current borrowings for acquisitions and ongoing expansions.
Order book
- →The transcript does not explicitly mention a specific current or expected order book or pending orders.
- →It does detail ongoing and upcoming expansion projects including:
- → - 397 beds at Patparganj with environmental clearance and tendering underway.
- → - 550 beds at Max Vikrant (Saket Complex) pending forest department clearance, expected completion by 2028.
- → - 400 beds at Zirakpur (Mohali), awaiting environmental clearance, with a 30-month completion timeline.
- → - 140 beds at Vaishali brownfield project planned, expected completion within 30 months.
- →The company plans to add around 1,500 beds in FY26 through brownfield expansions and greenfield projects like Nanavati (268 beds), Mohali (155 beds), Max Smart, and Gurgaon Sec-56.
- →Expansion is mostly funded through internal accruals with leverage room up to 2.5x net debt to EBITDA.
- →The company generated INR 1,447 crore free cash flow and is actively deploying capital into expansion and acquisitions.
Capex plans
Yes- →Max Healthcare is undertaking multiple expansion projects:
- → - 268 beds at Nanavati (Phase I) with commissioning expected within 90 days.
- → - 155 beds at Mohali with commissioning also expected within 90 days; plans to add 45 more beds post-tower completion.
- → - A built-to-suit hospital in Gurgaon (Sec-56) to be completed by end of calendar year.
- → - Brownfield expansions at Max Smart and other locations adding approximately 1,500 beds in FY '26.
- →18 acres of land in Noida with potential to add 1,000+ beds; current occupancy at 50%.
- →Land acquisition of around 1 acre adjacent to fully occupied Vaishali hospital; brownfield expansion expected within 30 months.
- →Environmental clearance and tendering in progress for 397 beds at Patparganj, 550 beds at Max Saket, and 400 beds at Zirakpur (Mohali).
- →Overall focus on asset-light expansion, brownfield additions, and internal accrual funding; no major debt increase planned unless acquisitions occur.
How does Max Healthcare Institute Ltd rank vs peers in Healthcare Services?
Pro feature1Max Healthcare Institute Ltd
Rev 2Mar 3
See full Healthcare Services sector rankings
Want more stocks like Max Healthcare Institute Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio